Plozasiran Trials

Plozasiran Cuts Triglycerides About 80% and Greatly Lowers Pancreatitis Risk in Phase III Trials

One-year randomized data show an RNA interference drug that reduces APOC3 may offer a new treatment option for people with severe hypertriglyceridaemia.